Arcutis Biotherapeutics, Inc. (ARQT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on dermatological diseases. The company's primary revenue driver is the ZORYVE® (roflumilast) product line, which includes formulations for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. During the quarter, the company launched ZORYVE foam for scalp and body psoriasis in the U.S. and ZORYVE cream 0.15% in Canada.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Revenues | $81,504 | $30,858 | $147,350 | $80,427 |
| Product Revenue (Net) | $81,504 | $30,858 | $145,350 | $52,427 |
| Net Loss | $(15,886) | $(52,332) | $(40,946) | $(87,714) |
| Operating Loss | $(14,611) | $(50,077) | $(39,140) | $(81,699) |
| Cash & Marketable Securities | $190,823 | $227,955 | $190,823 | $227,955 |
| Long-Term Debt (Principal) | $100,000 | $100,000 | $100,000 | $100,000 |
| Net Cash Used in Operating Activities (6mo) | $(30,056) | $(76,722) | $(30,056) | $(76,722) |
Note: Other revenue for the six months ended June 30, 2025, was $2.0 million, primarily from the Huadong license agreement. Q2 2025 had no other revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 164% in Q2 2025 compared to Q2 2024, driven by the commercial launch of ZORYVE foam for scalp psoriasis in June 2025 and continued growth in ZORYVE cream and foam sales.
- Profitability Improvement: Net loss narrowed significantly from $52.3 million in Q2 2024 to $15.9 million in Q2 2025. Operating loss improved from $50.1 million to $14.6 million.
- Expense Management: Research and Development (R&D) expenses remained relatively flat in Q2 ($19.5M vs $19.3M) but decreased 13% on a six-month basis ($37.0M vs $42.4M) due to the completion of Phase 3 studies for roflumilast cream in atopic dermatitis and reduced early-stage program costs.
- Interest Expense Reduction: Interest expense decreased by $4.5 million in Q2 2025 compared to the prior year, attributed to a $100 million principal paydown in October 2024 and lower interest rates.
- Debt Structure: The company maintains $100 million in outstanding principal under its Loan Agreement. A $100 million partial prepayment in late 2024 allowed for the potential re-draw of Tranche C loans, subject to revenue covenants.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing capital resources ($191.1 million in cash and marketable securities) are sufficient to meet operating requirements for at least 12 months. No immediate financing is anticipated, though future needs depend on commercialization success and R&D progress.
- Product Pipeline:
- ZORYVE: Submitted an sNDA for ZORYVE cream 0.05% for pediatric patients (2-5 years) in December 2024, with a PDUFA target date in October 2025. Initiated a Phase 2 study for infants (3 months to
- ARQ-255: Development of this topical JAK inhibitor for alopecia areata was halted following a Phase 1b study in mid-2025.
- ARQ-234: Submitted an IND application in July 2025 for this CD200R agonist for atopic dermatitis.
- Commercial Partnerships: A co-promotion agreement with Kowa Pharmaceuticals for primary care and pediatrics began in late September 2024.
- Legal Proceedings: Patent litigation against Padagis regarding a generic ZORYVE cream was stayed in April 2025 at the request of Padagis. The 30-month stay on FDA approval of the generic is extended for the duration of the stay. Oppositions to European patents by Teva are ongoing with oral proceedings scheduled for late 2025 and early 2026.
- Risk Factors: New U.S. federal tax legislation (the "One Big Beautiful Bill Act" signed July 4, 2025) includes Medicaid spending cuts that could impact revenue. The company is analyzing the potential impact.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of ZORYVE foam sales following the June 2025 scalp psoriasis launch and the impact of the Kowa co-promotion agreement.
- Debt Covenants: Confirm compliance with the minimum net product revenue covenant (75% of projected revenue) required to access Tranche C-1 and C-2 term loans.
- Regulatory Milestones: Monitor the FDA decision on the ZORYVE cream 0.05% sNDA for pediatric patients (target October 2025) and the progress of the infant study.
- Patent Litigation: Track the status of the stayed litigation with Padagis and the outcome of Teva's oppositions to European patents.
- Cost Structure: Assess the impact of the halted ARQ-255 program on future R&D spend and the trajectory of SG&A expenses as commercialization scales.